Patient Stories|VPRIV® (velaglucerase alfa) for injection

FEEL EMPOWERED TO PRESCRIBE
VPRIV AS A FIRST-LINE TREATMENT
FOR YOUR TYPE 1 GAUCHER PATIENTS

Make VPRIV your choice for patients during various stages of life.^1,2

Michael

Name: Michael
Age: 47
Age at type 1 Gaucher diagnosis: 43
Ethnicity: African American
Treatment history:
VPRIV, 4 years
Symptoms at baseline:
Moderately enlarged spleen and liver, severe thrombocytopenia, low hemoglobin, reduced bone mineral density³
Last check-up:
Maintained improvements in spleen volume, hemoglobin count, and platelet count^1,4,5

^*Not an actual patient. This is a hypothetical patient profile.

Name: Michael
Age: 47
Age at type 1 Gaucher diagnosis: 43
Ethnicity: African American
Treatment history: VPRIV, 4 years
Symptoms at baseline:
Moderately enlarged spleen and liver, severe thrombocytopenia, low hemoglobin, reduced bone mineral density³
Last check-up:
Maintained improvements in spleen volume, hemoglobin count, and platelet count^1,4,5

Michael had experienced persistent fatigue and easy bruising⁴ for many years before receiving an incorrect diagnosis of immune thrombocytopenic purpura (ITP) in his 30s.⁵

His symptoms had progressed by the time he was correctly diagnosed, at the age of 43, with type 1 Gaucher disease.⁶

The geneticist who diagnosed Michael recommended starting treatment immediately. Michael and his doctor discussed treatment options and selected VPRIV. Once Michael had been prescribed VPRIV, he was able to utilize the QuickStart program to receive his first infusion while his prior authorization was being reviewed.

Consider

If patients are eligible, the QuickStart program allows for up to two free infusions while the patient’s prior authorization is still being reviewed.

Looking to start your patients on VPRIV? Start the process by downloading a OnePath^® Start Form and filling it in with your patients to begin. Please contact OnePath^® at 1-866-888-0660 with any questions.

VPRIV OnePath® Start Form

Download the full VPRIV Patient Profiles here.

VPRIV Patient Profiles

VPRIV
Clinical Trials

Safety &
Tolerability Profile

Takeda Support Programs

STAY CONNECTED!

Fill in the required fields to stay up to date with news and announcements about VPRIV.

FIRST NAME*

LAST NAME*

EMAIL ADDRESS*

I agree to receive email communications with updates concerning product information, disease education, events, patient support programs and other topics from Takeda.

Your privacy is important to us. For more information, please refer to our Privacy Notice. To manage your communication preferences visit our preference center.

By providing your information you certify that you are a US healthcare professional.

US-VEL-0505v2.0 02/23

FEEL EMPOWERED TO PRESCRIBE VPRIV AS A FIRST-LINE TREATMENT FOR YOUR TYPE 1 GAUCHER PATIENTS

Consider

FEEL EMPOWERED TO PRESCRIBE
VPRIV AS A FIRST-LINE TREATMENT
FOR YOUR TYPE 1 GAUCHER PATIENTS